spacer
home > ebr > autumn 2018 > protein progression
PUBLICATIONS
European Biopharmaceutical Review

Protein Progression

Microarrays offer a well-established bioanalytical format for high-throughput studies of many different biomolecules. In the field of peptide and protein microarrays, great progress has been achieved in immobilising large numbers of native target molecules, such as recombinant human proteins or peptide libraries to microarray surfaces. With an increased content at high quality, protein and peptide microarrays offer new possibilities in proteomics and pharmaceutical R&D. Simultaneously, label-free sensing has evolved from highly sophisticated, but low-throughput, to powerful multiplexed screening tools. The combination of these advancements opens a new field of bioanalytics.

Analysis at a Glance

Proteins are involved in almost any process of a living cell. Therefore, proteomics is a key discipline of modern life sciences today. Furthermore, protein-protein interactions of human cells (the so-called human interactome, see Figure 1) and the interactions of proteins with other biomolecules are key for understanding any physiological process and manipulating it (eg, by a pharmaceutical or biopharmaceutical drug).

Protein scientists have developed different bioanalytical approaches based on proteins immobilised in a microarray format. Here, the focus lies on protein microarrays representing a set of species-specific (in most cases, human) proteins to study the binding of a specific molecule or sample to these target proteins in a single assay. The trend is towards a fraction up to the complete genetically encoded proteome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Güenther Proll is Co-Founder and Managing Director at Biametrics and has more than 18 years’ experience in optical biosensing. Güenther’s work is focussed on the characterisation and development of optical transduction technologies, spatially resolved surface chemistry on diverse substrates, and multianalyte/multiplex assay developments. He holds a diploma in technical biology from the University of Stuttgart, Germany, and a PhD in physical chemistry from the University of Tuebingen, Germany.
spacer
Dr Güenther Proll
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Continues Commitment to Oncology Drug Discovery

Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement